MANNKIND CORP Proceeds from Issuance of Private Placement
MANNKIND CORP (MNKD) reported Proceeds from Issuance of Private Placement of $28.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2020-02-25
- MANNKIND CORP proceeds from issuance of private placement for the quarter ending 2018-12-31 was $0.00.
- MANNKIND CORP proceeds from issuance of private placement for the quarter ending 2018-09-30 was $0.00.
- MANNKIND CORP proceeds from issuance of private placement for the quarter ending 2016-12-31 was $0.00.
- MANNKIND CORP proceeds from issuance of private placement for the quarter ending 2016-09-30 was $0.00.
- MANNKIND CORP proceeds from issuance of private placement for fiscal 2018 was $28.00M, a 54.10% decline from fiscal 2017.
- MANNKIND CORP proceeds from issuance of private placement for fiscal 2017 was $61.00M, a 22.00% increase from fiscal 2016.
- MANNKIND CORP proceeds from issuance of private placement for fiscal 2016 was $50.00M.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $28.00M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $28.00M 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $28.00M 10-Q · filed 2019-08-07 | |||
| 2017-12-31 | $61.00M 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $0.00 derived: sum of 2 quarters · filed 2019-02-26 | $50.00M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $50.00M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $50.00M 10-Q · filed 2017-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |